Live demo of end-to-end interoperability: specimen accessioning, ordering, and processing in the Laboratory Information System (LIS); image acquisition from grossing, electron microscopy, radiographic imaging, immunofluorescence, polarized light, and glass slide scanning across multiple vendor scanners; Quality Control (QC) with Artificial Intelligence (AI) and manual review; final case review in the Picture Archiving and Communication System (PACS); and results reporting to the Electronic Health Record (EHR).

Live demo of end-to-end interoperability: specimen accessioning, ordering, and processing in the Laboratory Information System (LIS); image acquisition from grossing, electron microscopy, radiographic imaging, immunofluorescence, polarized light, and glass slide scanning across multiple vendor scanners; Quality Control (QC) with Artificial Intelligence (AI) and manual review; final case review in the Picture Archiving and Communication System (PACS); and results reporting to the Electronic Health Record (EHR).

Learn about Danaher Diagnostics and Leica Biosystems vision of the future of digital and computational pathology. This session will present Leica Biosystems strategic vision for digital pathology, emphasizing its integration of pathology imaging and AI through Aperio platforms. The session will explore the transformative potential of computational pathology, with insights from leading academic partners on AI deployment and health system adoption. Finally, the wrap-up will introduce Leica Biosystems approach to partnering for co-developing companion diagnostics, highlighting the role of CDx in accelerating precision medicine and improving patient care.

The landscape of precision medicine is evolving at rapid speed, requiring new technologies to meet this demand. Computational pathology is a potentially transformative AI technology currently being used for the next generation of novel companion diagnostics. This workshop features a dynamic panel discussion on future trends, delving into the complexities and potential impact of computational pathology companion diagnostics.

-Discuss Computational Pathology in Drug Development & Regulatory Considerations: Understand the use of computational pathology in clinical trials and review the regulatory considerations needed to approve companion diagnostics which include AI.

-Navigate Reimbursement Pathways: Identify critical considerations for reimbursement to bridge the gap between diagnostics development and clinical adoption

-Build the Business Case: Explore the clinical, operational and financial considerations that drive lab decisions to adopt computational pathology

-Explore Practical Implementation: Dive into real-world laboratory requirements for implementing and validating computational pathology workflows, emphasizing operational feasibility.

Join us to connect emerging technologies to laboratory decision-making, ensuring a clear business case for adoption and implementation.